Kenvue Inc. (NYSE:KVUE) Shares Sold by Chevy Chase Trust Holdings LLC

Chevy Chase Trust Holdings LLC reduced its stake in Kenvue Inc. (NYSE:KVUE) by 0.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,007,097 shares of the company’s stock after selling 831 shares during the quarter. Chevy Chase Trust Holdings LLC’s holdings in Kenvue were worth $24,150,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in KVUE. Fulton Bank N.A. grew its stake in Kenvue by 0.6% in the 1st quarter. Fulton Bank N.A. now owns 78,888 shares of the company’s stock worth $1,892,000 after acquiring an additional 465 shares during the period. SRS Capital Advisors Inc. boosted its holdings in shares of Kenvue by 67.4% during the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock worth $30,000 after purchasing an additional 571 shares during the last quarter. Keystone Financial Group grew its position in shares of Kenvue by 4.8% in the fourth quarter. Keystone Financial Group now owns 12,736 shares of the company’s stock valued at $272,000 after purchasing an additional 578 shares during the period. Transatlantique Private Wealth LLC grew its position in shares of Kenvue by 5.7% in the fourth quarter. Transatlantique Private Wealth LLC now owns 10,680 shares of the company’s stock valued at $228,000 after purchasing an additional 580 shares during the period. Finally, Sound View Wealth Advisors Group LLC increased its stake in Kenvue by 6.3% in the fourth quarter. Sound View Wealth Advisors Group LLC now owns 9,985 shares of the company’s stock valued at $213,000 after purchasing an additional 590 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

Kenvue stock opened at $21.17 on Thursday. The firm has a market capitalization of $40.62 billion, a PE ratio of 38.49, a price-to-earnings-growth ratio of 3.29 and a beta of 0.98. Kenvue Inc. has a one year low of $17.67 and a one year high of $25.17. The stock’s 50 day moving average price is $22.93 and its 200 day moving average price is $22.39. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.60 and a current ratio of 0.86.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. The company had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. Kenvue had a net margin of 6.90% and a return on equity of 20.87%. The business’s quarterly revenue was down 3.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.28 earnings per share. As a group, sell-side analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were given a $0.205 dividend. The ex-dividend date was Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a yield of 3.87%. Kenvue’s payout ratio is currently 149.09%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Barclays raised their price target on Kenvue from $22.00 to $23.00 and gave the stock an “equal weight” rating in a research note on Monday, May 12th. Canaccord Genuity Group raised their target price on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Citigroup restated a “neutral” rating on shares of Kenvue in a report on Friday, June 13th. Redburn Atlantic began coverage on shares of Kenvue in a research note on Thursday, April 10th. They set a “neutral” rating and a $23.50 price target on the stock. Finally, UBS Group lifted their price target on shares of Kenvue from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Friday, May 9th. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $25.33.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.